Log in

NASDAQ:CMRXChimerix Stock Price, Forecast & News

$3.41
+0.18 (+5.57 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.19
Now: $3.41
$3.43
50-Day Range
$3.01
MA: $3.24
$3.72
52-Week Range
$1.19
Now: $3.41
$3.88
Volume415,768 shs
Average Volume468,940 shs
Market Capitalization$211.18 million
P/E RatioN/A
Dividend YieldN/A
Beta1.9
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Read More
Chimerix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.52 million
Book Value$1.79 per share

Profitability

Net Income$-112,580,000.00
Net Margins-923.87%

Miscellaneous

Employees82
Market Cap$211.18 million
Next Earnings Date8/10/2020 (Confirmed)
OptionableOptionable
$3.41
+0.18 (+5.57 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chimerix (NASDAQ:CMRX) Frequently Asked Questions

How has Chimerix's stock been impacted by COVID-19 (Coronavirus)?

Chimerix's stock was trading at $1.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CMRX stock has increased by 136.8% and is now trading at $3.41.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Chimerix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chimerix
.

When is Chimerix's next earnings date?

Chimerix is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Chimerix
.

How were Chimerix's earnings last quarter?

Chimerix Inc (NASDAQ:CMRX) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.02. The biopharmaceutical company earned $1.24 million during the quarter, compared to the consensus estimate of $1.50 million. Chimerix had a negative return on equity of 34.16% and a negative net margin of 923.87%.
View Chimerix's earnings history
.

What price target have analysts set for CMRX?

1 Wall Street analysts have issued 1-year target prices for Chimerix's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Chimerix's share price to reach $7.00 in the next year. This suggests a possible upside of 105.3% from the stock's current price.
View analysts' price targets for Chimerix
.

Has Chimerix been receiving favorable news coverage?

News headlines about CMRX stock have trended negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chimerix earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Chimerix
.

Are investors shorting Chimerix?

Chimerix saw a increase in short interest in July. As of July 31st, there was short interest totaling 1,250,000 shares, an increase of 5.0% from the July 15th total of 1,190,000 shares. Based on an average daily trading volume, of 1,080,000 shares, the short-interest ratio is presently 1.2 days. Currently, 2.7% of the company's shares are sold short.
View Chimerix's Short Interest
.

Who are some of Chimerix's key competitors?

What other stocks do shareholders of Chimerix own?

Who are Chimerix's key executives?

Chimerix's management team includes the following people:
  • Mr. Timothy W. Trost, Sr. VP, CFO & Corp. Sec. (Age 61)
  • Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 50)
  • Mr. Michael A. Sherman, CEO & Pres (Age 53)
  • Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier Ph.D., Chief Science Officer

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Who are Chimerix's major shareholders?

Chimerix's stock is owned by many different retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.10%), Vanguard Capital Wealth Advisors (0.05%), SG Americas Securities LLC (0.04%), UBS Group AG (0.03%), Marquette Asset Management LLC (0.03%) and Virtu Financial LLC (0.03%). Company insiders that own Chimerix stock include Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends for Chimerix
.

Which major investors are selling Chimerix stock?

CMRX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Marquette Asset Management LLC.
View insider buying and selling activity for Chimerix
.

Which major investors are buying Chimerix stock?

CMRX stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Vanguard Capital Wealth Advisors, Virtu Financial LLC, and SG Americas Securities LLC. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, Martha J Demski, Michael A Sherman, Michael T Andriole, and Robert J Meyer.
View insider buying and selling activity for Chimerix
.

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $3.41.

How big of a company is Chimerix?

Chimerix has a market capitalization of $211.18 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Chimerix employs 82 workers across the globe.

What is Chimerix's official website?

The official website for Chimerix is www.chimerix.com.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.